Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications

被引:0
|
作者
Sudesh Vasdev
Vicki Gill
Pawan Singal
机构
[1] Memorial University of Newfoundland,Discipline of Medicine, Faculty of Medicine, Room H
[2] University of Manitoba,4310, Health Sciences Centre
来源
Cell Biochemistry and Biophysics | 2007年 / 49卷
关键词
Hypertension; Atherosclerosis; Advanced glycation end products; Insulin resistance; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
The vascular diseases, hypertension and atherosclerosis, affect millions of individuals worldwide, and account for a large number of deaths globally. A better understanding of the mechanism of these conditions will lead to more specific and effective therapies. Hypertension and atherosclerosis are both characterized by insulin resistance, and we suggest that this plays a major role in their etiology. The cause of insulin resistance is not known, but may be a result of a combination of genetic and lifestyle factors. In insulin resistance, alterations in glucose and lipid metabolism lead to the production of excess aldehydes including glyoxal and methylglyoxal. These aldehydes react non-enzymatically with free amino and sulfhydryl groups of amino acids of proteins to form stable conjugates called advanced glycation end products (AGEs). AGEs act directly, as well as via receptors to alter the function of many intra- and extracellular proteins including antioxidant and metabolic enzymes, calcium channels, lipoproteins, and transcriptional and structural proteins. This results in endothelial dysfunction, inflammation and oxidative stress. All these changes are characteristic of hypertension and atherosclerosis. Human and animal studies have demonstrated that increased AGEs are also associated with these conditions. A pathological role for AGEs is substantiated by studies showing that therapies that attenuate insulin resistance and/or lower AGEs, are effective in decreasing oxidative stress, lowering blood pressure, and attenuating atherosclerotic vascular changes. These interventions include lipoic acid and other antioxidants, AGE breakers or soluble receptors of AGEs, and aldehyde-binding agents like cysteine. Such therapies may offer alternative specific means to treat hypertension and atherosclerosis. An adjunct therapy may be to implement lifestyle changes such as weight reduction, regular exercise, smoking cessation, and increasing dietary intake of fruits and vegetables that also decrease insulin resistance as well as oxidative stress.
引用
收藏
页码:48 / 63
页数:15
相关论文
共 50 条
  • [11] Advanced Glycation End Products and Cardiovascular Disease
    Peppa, Melpomeni
    Raptis, Sotirios A.
    CURRENT DIABETES REVIEWS, 2008, 4 (02) : 92 - 100
  • [12] Dietary Advanced Glycation End Products and Their Role in Health and Disease
    Uribarri, Jaime
    Dolores del Castillo, Mara
    Pia de la Maza, Mara
    Filip, Rosana
    Gugliucci, Alejandro
    Luevano-Contreras, Claudia
    Macias-Cervantes, Maciste H.
    Markowicz Bastos, Deborah H.
    Medrano, Alejandra
    Menini, Teresita
    Portero-Otin, Manuel
    Rojas, Armando
    Sampaio, Geni Rodrigues
    Wrobel, Kazimierz
    Wrobel, Katarzyna
    Eugenia Garay-Sevilla, Ma
    ADVANCES IN NUTRITION, 2015, 6 (04) : 461 - 473
  • [13] The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach
    Salahuddin, Parveen
    Rabbani, Gulam
    Khan, Rizwan Hasan
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2014, 19 (03) : 407 - 437
  • [14] Advanced glycation end products and risk of hypertension in Iranian adults: Tehran lipid and glucose study
    Mirmiran, Parvin
    Yousefi, Reyhaneh
    Mottaghi, Azadeh
    Azizi, Fereidoun
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2018, 23
  • [15] Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention
    Yamagishi, Sho-ichi
    Matsui, Takanori
    NUTRITION, 2016, 32 (02) : 157 - 165
  • [16] Accumulation of Advanced Glycation End Products in Canine Atherosclerosis
    Chiers, K.
    Vandenberge, V.
    Ducatelle, R.
    JOURNAL OF COMPARATIVE PATHOLOGY, 2010, 143 (01) : 65 - 69
  • [17] Role of Receptor for Advanced Glycation End Products (RAGE) in Regression of Diabetic Atherosclerosis
    Senatus, Laura M.
    Lopez-Diez, Raquel
    Liu, Jianhua
    Li, Huilin
    Daffu, Gurdip
    Li, Qing
    Rahman, Karishma
    Vengrenyuk, Yuliya
    Barrett, Tessa
    Friedman, Richard
    Ramasamy, Ravichandran
    Fisher, Edward
    Schmidt, AnnMarie
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37
  • [18] Advanced glycation end-products and arterial stiffness in hypertension
    McNulty, Marie
    Mahmud, Azra
    Feely, John
    AMERICAN JOURNAL OF HYPERTENSION, 2007, 20 (03) : 242 - 247
  • [19] Role of advanced glycation end products in cardiovascular disease
    Hegab, Zeinab
    Gibbons, Stephen
    Neyses, Ludwig
    Mamas, Mamas A.
    WORLD JOURNAL OF CARDIOLOGY, 2012, 4 (04): : 90 - 102
  • [20] A Role for Advanced Glycation End Products in Molecular Ageing
    Zgutka, Katarzyna
    Tkacz, Marta
    Tomasiak, Patrycja
    Tarnowski, Maciej
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (12)